Patents Assigned to MorphoSys AG
-
Publication number: 20140227277Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.Type: ApplicationFiled: August 14, 2012Publication date: August 14, 2014Applicant: MorphoSys AGInventors: Jutta Amersdorffer, Stefan Steidl, Mark Winderlich, Susanne Krohn, Lisa Rojkjaer
-
Publication number: 20140206575Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.Type: ApplicationFiled: April 2, 2014Publication date: July 24, 2014Applicant: MorphoSys AGInventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
-
Publication number: 20140205608Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: July 17, 2012Publication date: July 24, 2014Applicants: MorphoSys AG, The University of MelbourneInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Publication number: 20140163208Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: ApplicationFiled: January 31, 2014Publication date: June 12, 2014Applicant: MorphoSys AGInventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Patent number: 8735099Abstract: New vectors expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. The new vector can be used for the regulated heterologous expression of a nucleic acid sequence in a prokaryotic host. There is an isolated and purified nucleic acid sequence expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes a nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. A prokaryotic host is transformed with the vector or the isolated and purified nucleic acid sequence. There is a method for producing a polypeptide in a host using the vector.Type: GrantFiled: April 27, 2011Date of Patent: May 27, 2014Assignee: Morphosys AGInventors: Johann Brass, Joachim Klein, Ralf Ostendorp
-
Patent number: 8728981Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.Type: GrantFiled: November 18, 2011Date of Patent: May 20, 2014Assignee: MorphoSys AGInventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
-
Publication number: 20140120115Abstract: The present disclosure relates to antigen-binding moieties that specifically bind to MIF and D-DT and compositions and methods of use thereof.Type: ApplicationFiled: July 13, 2012Publication date: May 1, 2014Applicant: MorphoSys AGInventors: Swen Zierow, Juergen Klattig
-
Patent number: 8685896Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: GrantFiled: May 29, 2010Date of Patent: April 1, 2014Assignee: MorphoSys AGInventors: Markus Enzelberger, Stefanie Urlnger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Publication number: 20140011698Abstract: The present invention provides methods, immunoassays, kits and devices pertaining to the detection of multiple biomolecules from single cells or other biological entities. It also enables the highly parallel detection of interacting biomolecules from such entities.Type: ApplicationFiled: November 30, 2011Publication date: January 9, 2014Applicants: MorphoSys AG, ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG, HSG-IMIT Institut für Mikro-und InformationstechnikInventors: Markus Enzelberger, Andreas Boll, Beate Diefenbach-Streiber, Guenter Roth, Felix von Stetten, Fabian Stumpf
-
Patent number: 8551733Abstract: The present invention provides methods to produce mixtures of exogenous proteins in single cells. Preferably said exogenous proteins are heteromeric and multimeric proteins, such as immunoglobulins. The method enables the controlled expression of proteins, thereby allowing the correct formation and assembly of multimeric proteins, such as immunoglobulins.Type: GrantFiled: February 8, 2010Date of Patent: October 8, 2013Assignee: MorphoSys AGInventor: Markus Enzelberger
-
Publication number: 20130236902Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.Type: ApplicationFiled: November 18, 2011Publication date: September 12, 2013Applicant: MorphoSys AGInventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
-
Patent number: 8513164Abstract: The present invention relates to a method of identifying one or more genes encoding one or more proteins having an optimized property. In particular, the method comprises expressing a collection of genes and screening for a desired property, identifying a plurality of genes having the desired property, and replacing one or more one or more sub-sequences of each of said genes with a different, compatible genetic sub-sequence, and screening again in order to identify genes encoding proteins having an optimized property.Type: GrantFiled: December 21, 2006Date of Patent: August 20, 2013Assignee: MorphoSys AGInventors: Achim Knappik, Peter Pack, Liming Ge, Simon Moroney, Andreas Plückthun
-
Patent number: 8486394Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: GrantFiled: November 8, 2011Date of Patent: July 16, 2013Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Publication number: 20130136747Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: November 8, 2012Publication date: May 30, 2013Applicants: MORPHOSYS AG, HOFFMANN-LA ROCHE INC.Inventors: Hoffmann-La Roche Inc., Morphosys AG
-
Patent number: 8367586Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.Type: GrantFiled: November 18, 2011Date of Patent: February 5, 2013Assignee: MorphoSys AGInventors: Stefanie Urlinger, Thomas Tiller, Ingrid Schuster, Yvonne Stark
-
Publication number: 20130030157Abstract: The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.Type: ApplicationFiled: January 28, 2011Publication date: January 31, 2013Applicant: MORPHOSYS AGInventors: Josef Prassler, David Ott, Stefanie Thiel, Yvonne Stark, Ute Keck, Thomas Pietzonka, Hilmar Ebersbach
-
Patent number: 8329886Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: May 16, 2012Date of Patent: December 11, 2012Assignees: Hoffman-La Roche Inc., Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8273688Abstract: The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR3) members, where diversity of the collection is a function of the length of the HCDR3 members. The diversity of the collection of HCDR3 regions substantially represents the natural amino acid distribution of HCDR3 in the human repertoire. This natural amino acid distribution can be represented by biasing the complete random distribution of amino acids, accordingly, in the HCDR3 encoding DNA sequence by using trinucleotide mutagenesis (TRIM) technology. A collection of HCDR3 members of the invention each can be comprised within a variable region of an antibody (or fragment thereof) to form a library of synthetic antibodies or antibody fragments. The invention also provides nucleic acid molecules encoding such diverse collection and methods of making and using the same.Type: GrantFiled: December 15, 2006Date of Patent: September 25, 2012Assignee: MorphoSys AGInventors: Markus Enzelberger, Stefanie Thiel, Josef Prassler, Stefanie Urlinger, Christine Rothe
-
Patent number: 8263746Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: GrantFiled: February 7, 2005Date of Patent: September 11, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jager
-
Publication number: 20120178909Abstract: The present invention discloses novel screening strategies for the identification of binders that target the active site of enzymatic antigens. The present invention also discloses antigen-binding moieties which bind to the NS2B-NS3 Proteinase of West Nile Virus, in particular binders which bind to the active site, thereby inhibiting the enzymatic activity of the proteinase. The antigen-binding moieties of the present invention have numerous therapeutic and diagnostic applications.Type: ApplicationFiled: August 6, 2010Publication date: July 12, 2012Applicant: MORPHOSYS AGInventors: Christian Frisch, Achim Knappik, Alex Y. Strongin, Sergey A. Shiryaev